Reports


Global Acute Myeloid Leukemia Treatment Market 2020-2029 (Includes Business Impact of COVID-19)

  • TBI70449
  • October 22, 2020
  • Global
  • 93 pages
  • QY Market Research
                                              Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. AML is a complex and challenging disease with generally low survival rates.

The global Acute Myeloid Leukemia Treatment market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acute Myeloid Leukemia Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Myeloid Leukemia Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

Segment by Regions
  • North America
  • Europe
  • China
  • Japan
Segment by Type
  • DC regimen
  • AVD Regimen
  • VCD regimen
Segment by Application
  • Hospital
  • Clinic
  • Others
In October 2020, AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. The FDA previously granted accelerated approval to VENCLEXTA for this indication in 2018. The cost for Venclexta oral kit (50 mg-100 mg) is around $3,200 for a supply of 30 kits. VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. VENCLEXTA is approved in more than 50 countries, including the U.S. In July 2020, European Commission Approved DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Pfizer Inc. (NYSE:PFE) announced that the European Commission approved DAURISMO™ (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy. The approval follows the medicine’s positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) earlier this year, as well as the medicine’s approval by the U.S. Food and Drug Administration (FDA) in November 2018. The European Commission’s approval of DAURISMO is based on results from the Phase 2 BRIGHT 1003 trial, which showed DAURISMO nearly doubled median overall survival compared to LDAC alone (8.3 months vs. 4.3 months, HR 0.463, 95% CI [0.299,0.717]) in patients with previously untreated (de novo or secondary) AML who were not eligible for intensive chemotherapy. The difference represented a 54 percent reduction in the risk of death for patients treated with DAURISMO plus LDAC (HR: 0.463, 95% CI: 0.299, 0.717, one-sided p-value 0.0002) DAURISMO in combination with low-dose cytarabine nearly doubled overall survival compared to low-dose cytarabine alone. People with previously untreated acute myeloid leukemia who cannot withstand intensive chemotherapy are in urgent need of new options and using this new therapy that may extend survival for appropriate patients. DAURISMO is a once-daily oral Hedgehog pathway inhibitor, taken in combination with LDAC. In the EU, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy. In the U.S. and Canada, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.

Table of Contents

Executive Summary
1 Acute Myeloid Leukemia Treatment Market Overview
    1.1 Product Overview and Scope of Acute Myeloid Leukemia Treatment
    1.2 Acute Myeloid Leukemia Treatment Segment by Type
        1.2.1 Global Acute Myeloid Leukemia Treatment Production Growth Rate Comparison by Type (2014-2025)
        1.2.2 DC regimen
        1.2.3 AVD Regimen
        1.2.4 VCD regimen
    1.3 Acute Myeloid Leukemia Treatment Segment by Application
        1.3.1 Acute Myeloid Leukemia Treatment Consumption Comparison by Application (2014-2025)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Acute Myeloid Leukemia Treatment Market by Region
        1.4.1 Global Acute Myeloid Leukemia Treatment Market Size Region
        1.4.2 North America Status and Prospect (2014-2025)
        1.4.3 Europe Status and Prospect (2014-2025)
        1.4.4 China Status and Prospect (2014-2025)
        1.4.5 Japan Status and Prospect (2014-2025)
    1.5 Global Acute Myeloid Leukemia Treatment Market Size
        1.5.1 Global Acute Myeloid Leukemia Treatment Revenue (2014-2025)
        1.5.2 Global Acute Myeloid Leukemia Treatment Production (2014-2025)

2 Global Acute Myeloid Leukemia Treatment Market Competition by Manufacturers
    2.1 Global Acute Myeloid Leukemia Treatment Production Market Share by Manufacturers (2014-2019)
    2.2 Global Acute Myeloid Leukemia Treatment Revenue Share by Manufacturers (2014-2019)
    2.3 Global Acute Myeloid Leukemia Treatment Average Price by Manufacturers (2014-2019)
    2.4 Manufacturers Acute Myeloid Leukemia Treatment Production Sites, Area Served, Product Types
    2.5 Acute Myeloid Leukemia Treatment Market Competitive Situation and Trends
        2.5.1 Acute Myeloid Leukemia Treatment Market Concentration Rate
        2.5.2 Acute Myeloid Leukemia Treatment Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Acute Myeloid Leukemia Treatment Production Market Share by Regions
    3.1 Global Acute Myeloid Leukemia Treatment Production Market Share by Regions
    3.2 Global Acute Myeloid Leukemia Treatment Revenue Market Share by Regions (2014-2019)
    3.3 Global Acute Myeloid Leukemia Treatment Production, Revenue, Price and Gross Margin (2014-2019)
    3.4 North America ...
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form